Issue Type: Book Built Revenue : Low PAT : Low compared to Reveneu Debt : Low Debt, can be easily repaid. Overall Financials : Moderate. Company Valuation and Peer to peer Comparison: Seems Over Valued Anchor Investment : YES 👍 Product Market Fit : Good as demand for Pharma products keep on increasing Customer Base: Only Domestic Lead Manager & Registrar Track Record : Good Obejective of Issue: Set up of New Multi speciality Hospital which is a plus point👍 My Personel Opinion: Yes apply, keeping in mind long term vision.
6.1. Scrip| Link| Bookmark|
June 29, 2024 2:37:53 AM
Top Contributor (500+ Posts, 200+ Likes)
@Scrip Usually for Service company the PAT of 15 to 20 % of the Net Revenue is considered to be healthy. In case of Nephro for FY 2023 the PAT is around 10 to 11 % of the Revenue, which seems to be weak. I regret if my statement has caused any confusion for you. Happy Investing!